Piramal Pharma declined 1.30% to Rs 117.45 after the pharma company said that the United States Food and Drug Administration (USFDA) issued a Form 483, with six observations after the inspection of its Lexington facility.
The USFDA conducted a pre-approval inspection (PAI) and good manufacturing practices (GMP) inspection of Piramal Pharma's Lexington facility, Kentucky, USA from 27 December 2022 to 10 January 2023.The observations were classified under voluntary action indicated (VAI) and does not relate to data integrity, the company said.
The company added that it is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines.
Piramal Pharma lastly added that it remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
Piramal Pharma is a pharmaceutical company that manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. Piramal Pharma serves customers worldwide.
The company reported a net loss of Rs 37.34 crore in Q2 FY23 as against a net profit of Rs 36.56 crore in Q2 FY22. Net Sales rose 9% YoY to Rs 1,720.01 crore in the quarter ended 30 September 2022.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app